Developmental Research Program

项目摘要/摘要-DRP MSK胰腺孢子发育研究计划(DRP)的目标是扩大 扩大转化型胰腺癌研究基础，鼓励高度创新的研究 对胰腺癌的预后有很大的潜在影响。DRP基金，辅以机构基金， 将使我们能够每年支持2个特殊的试点项目。我们将通过以下方式征求试点项目建议书 明确的翻译重点并有可能最终影响胰腺癌患者的临床护理 肿瘤。有胰腺癌研究历史的研究人员(医学博士、医学博士、博士或博士) 被任命为MSK或邻近机构的威尔·康奈尔医学院和洛克菲勒大学将 有资格申请。申请将由CEP/DRP遴选委员会进行同行评审，该委员会是 由孢子PIs、DRP和CEP领导人组成，选定MSK部门和分区主席，以及 MSK平等、多样性和包容性理事会的代表。最有功绩的项目基于 将选择已定义的审查标准。将优先考虑促进长期研究的项目 目标的孢子，并有很高的潜力成为完整的孢子项目。我们将优先处理提交的项目 由早期调查人员提供，并致力于促进多样性和加强 妇女和翻译研究中代表性不足的群体。DRP获奖者将完全访问孢子 核心资源，将受益于孢子调查小组的专门知识，并将是积极的参与者 在孢子里。DRP项目的科学进展将由DRP领导人每六个月进行一次评估。 DRP获奖者的长期成功衡量标准包括介绍/发表原始研究、成功 竞争独立研究支持，成功开发和完成临床试验 从DRP研究，建立新的合作关系，以及学术界对机构的认可 升职。在实现翻译目标方面取得重大进展的DRP项目将有资格获得 第二年的资助，并有可能被推广到全孢子项目。

PROJECT SUMMARY/ABSTRACT – DRP The goals of the Developmental Research Program (DRP) of the MSK Pancreas SPORE are to expand the breadth of the translational pancreatic cancer research base and to encourage highly innovative investigations that have major potential to impact pancreatic cancer outcomes. DRP funds, supplemented by institutional funds, will allow us to support 2 exceptional pilot projects each year. We will request proposals for pilot projects with a clear translational focus and with potential to ultimately impact clinical care of patients with pancreatic neoplasms. Investigators (MD, MD/PhD, DO, or PhD) with a demonstrated history of pancreas cancer research appointed at MSK or a neighboring institution, Weill Cornell Medical College and the Rockefeller University, will be eligible to apply. Applications will be peer-reviewed by the CEP/DRP Selection Committee, which is composed of the SPORE PIs, DRP and CEP Leaders, select MSK Departmental and Divisional Chairs, and representatives from the MSK Equality, Diversity & Inclusion Council. The most meritorious projects based on defined review criteria will be selected. Preference will be given to projects that advance the long-term research goals of the SPORE and have high potential to become full SPORE projects. We will prioritize projects submitted by early-stage investigators and are committed to promoting diversity and strengthening the participation of women and underrepresented groups in translational research. DRP awardees will have full access to SPORE Core resources, will benefit from the expertise of the SPORE investigative team, and will be active participants in the SPORE. The scientific progress of DRP projects will be evaluated every six months by the DRP Leaders. Long-term metrics of success for DRP awardees include presentation/publication of original research, successful competition for independent research support, successful development and completion of clinical trials stemming from DRP research, establishment of new collaborations, and institutional recognition by academic promotion. DRP projects that make significant progress towards their translational goals will be eligible for a second year of funding and have the potential to be promoted to full SPORE projects.